Superior Clinical and Economic Value of <scp>IL</scp> ‐23 Inhibitors Versus Adalimumab Biosimilars in Plaque Psoriasis

Our study highlights the substantial clinical benefit of IL-23 inhibitors over adalimumab biosimilars, with guselkumab as the more cost-effective option than the other IL-23 inhibitors for the real-world management of moderate-to-severe psoriasis.